As a first-in-class triple receptor agonist , it has demonstrated robust metabolic effects in early clinical studies
While many patients experience benefits from taking GLP-1s, there are some fairly significant side effects associated with these medications
Zepbound is indicated for chronic weight management (FDA approved November 2023)
It doesn't mean prescriptions are automatic
Expansion of coverage under Medicare of GLP-1s to treat obesity under the BALANCE model is likely to increase utilization above current levels, as Medicare begins to meet the demand for obesity drugs among beneficiaries who have been unable to access or afford these medications to date
[DOI] [PMC free article] [PubMed] [Google Scholar] 31.Alsuhibani A, Alrasheed M, Gari M, Hincapie A L, Guo J J